Hossam Kamli^*, Gaffar S. Zaman^*, Ahmad Shaikh^*, Abdullah A. Mobarki^†, Prasanna Rajagopalan^*‡

Oncology Research, Vol.28, No.9, pp. 899-911, 2020, DOI:10.3727/096504021X16281573507558

Abstract Inhibition of the dihydroorotate dehydrogenase (DHODH) has been successful at the preclinical level in controlling myeloid leukemia. However, poor clinical trials warrant the search for new potent DHODH inhibitors. Herein we present a novel DHODH inhibitor SBL-105 effective against myeloid leukemia. Chemical characteristics were identified by ¹ H NMR, ¹³C NMR, and mass spectroscopy. Virtual docking and molecular dynamic simulation analysis were performed using the automated protocol with AutoDock-VINA, GROMACS program. Human-recombinant (rh) DHODH was used for enzyme inhibition study. THP-1, TF-1, HL-60, and SKM-1 cell lines were used. MTT assay was used to assess cell viability. Flow cytometry was… More >

Arisha Patel, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic Farah, Robert L. Redner, Annie Im, Kathleen A. Dorritie, Alison Sehgal, James Rossetti, Melissa Saul, Daniel Normolle, Konstantinos Lontos, Michael Boyiadzis

Oncology Research, Vol.28, No.7-8, pp. 811-814, 2020, DOI:10.3727/096504020X15965357399750

Abstract Leukemia relapse 5 years after achieving first complete remission (CR1) is uncommon in patients with acute myeloid leukemia (AML). In this study, we evaluated the outcomes of AML patients with late relapse at our institution and reviewed the literature for these patients. The study cohort consisted of nine AML patients with late relapse. The median interval between CR1 and AML relapse was 6.1 years (range: 5.1–16.2 years). At relapse, the karyotype was different from the initial AML diagnosis in 50% of patients. At the time of AML relapse, seven patients received induction chemotherapy and two patients received hypomethylating agents with… More >

Angela Silvano^*†1, Giulio Menegazzi^*1, Silvia Peppicelli^*1, Caterina Mancini^*, Alessio Biagioni^*, Alessandro Tubita^*, Ignazia Tusa^*, Jessica Ruzzolini^*, Matteo Lulli^*, Elisabetta Rovida^*, Persio Dello Sbarba^*

Oncology Research, Vol.29, No.1, pp. 33-46, 2021, DOI:10.3727/096504022X16442289212164

Abstract This study was directed to deepen the effects of nutrient shortage on BCR/Ablprotein expression and signaling in chronic myeloid leukemia (CML) cells. The backbone of the study was cell culture in medium lacking glucose, the consumption of which we had previously shown to drive BCR/Ablprotein suppression, and glutamine, the other main nutrient besides glucose. In this context, we focused on the role of lactate, the main by-product of glucose metabolism under conditions of rapid cell growth, in particular as a modulator of the maintenance of CML stem/progenitor cell potential, a crucial determinant of disease course and relapse of disease. The… More >

Khadija Khan, Samabia Tehsin^*

Journal on Artificial Intelligence, Vol.4, No.1, pp. 1-13, 2022, DOI:10.32604/jai.2022.028092

Abstract Leukemia is the cancer that starts in the blood cells due to the excess production of immature leucocytes that replace the cells with normal blood cells. Physicians rely on their experience to determine the type and subtype of Leukemia from the blood sample. Most people are misdiagnosed when it comes to its subtypes, the error rates can be up to 40% during the classification process. That too depends on the expertise of the physician. This research represents a Convolutional Neural Network based medical image classifier. The proposed technique can classify Leukemia and its five subtypes. State of the art deep… More >

Elsa Maitre, Xavier Troussard^*

Oncologie, Vol.24, No.1, pp. 3-24, 2022, DOI:10.32604/oncologie.2022.021490

Abstract Hairy cell leukemia (LT) accounts for 2% of all leukemias. The diagnosis is based on the presence in the blood and/ or the marrow of hairy cells expressing CD103, CD123, CD11c and CD25. The BRAF^V600E mutation, a molecular marker of the disease, is present in more than 80% of cases. LT should be distinguished from other chronic B-cell lymphoproliferative disorders, including the variant form of hairy cell leukemia (HCL-V) and diffuse splenic red pulp lymphoma (DSRPL). Progress has recently been made in the management of patients. The purine analogues (PNAs) in monotherapy, deoxycoformycin (DCF) or 2-chloro-deoxyadenosine (CDA), remain the first-line… More >

R. Kavitha^1,*, N. Viswanathan²

Intelligent Automation & Soft Computing, Vol.33, No.2, pp. 1305-1320, 2022, DOI:10.32604/iasc.2022.022816

Abstract Bone marrow cancer is considered to be the most complex and dangerous disease which results due to an uncontrolled growth of white blood cells called leukocytes. Acute Lymphoblastic Leukemia (ALL) and Multiple Myeloma (MM) are considered to be important categories of bone cancers, which induces a larger number of cancer cells in the bone marrow, results in preventing the production of healthy blood cells. The advent of Artificial Intelligence, especially machine and deep learning, has expanded humanity’s capacity to analyze and detect these increasingly complex diseases. But, accurate detection of cancer cells and reducing the probability of false alarm rates… More >

G. Sriram¹, T. R. Ganesh Babu², R. Praveena^2,*, J. V. Anand³

Molecular & Cellular Biomechanics, Vol.19, No.1, pp. 29-40, 2022, DOI:10.32604/mcb.2022.016966

Abstract Leukemoid reaction like leukemia indicates noticeable increased count of WBCs (White Blood Cells) but the cause of it is due to severe inflammation or infections in other body regions. In automatic diagnosis in classifying leukemia and leukemoid reactions, ALL IDB2 (Acute Lymphoblastic Leukemia-Image Data Base) dataset has been used which comprises 110 training images of blast cells and healthy cells. This paper aimed at an automatic process to distinguish leukemia and leukemoid reactions from blood smear images using Machine Learning. Initially, automatic detection and counting of WBC is done to identify leukocytosis and then an automatic detection of WBC blasts… More >

Abdul Karim¹, Azhari Azhari^1,*, Mobeen Shahroz², Samir Brahim Belhaouri³, Khabib Mustofa¹

CMC-Computers, Materials & Continua, Vol.71, No.2, pp. 3887-3903, 2022, DOI:10.32604/cmc.2022.021218

Abstract Leukemia is blood cancer, including bone marrow and lymphatic tissues, typically involving white blood cells. Leukemia produces an abnormal amount of white blood cells compared to normal blood. Deoxyribonucleic acid (DNA) microarrays provide reliable medical diagnostic services to help more patients find the proposed treatment for infections. DNA microarrays are also known as biochips that consist of microscopic DNA spots attached to a solid glass surface. Currently, it is difficult to classify cancers using microarray data. Nearly many data mining techniques have failed because of the small sample size, which has become more critical for organizations. However, they are not… More >

PENG YANG^1,*, ZHIYING ZOU¹, XULING GAO²

BIOCELL, Vol.46, No.1, pp. 207-218, 2022, DOI:10.32604/biocell.2021.014728

Abstract Recent studies have shown that the microtubule disrupting protein Stathmin 1 (STMN1) is differentially expressed in AML patients and healthy control. The aim of this study was to explore the effects and molecular mechanism of STMN1 in AML. Here, the expression of STMN1 in peripheral blood cells (PBMCs) and bone marrow of AML patients and healthy volunteers was detected by RT-PCR and Western blot. STMN1 expression was regulated by transfected with STMN1 overexpressed plasmid or shRNA in two human leukemia cell lines K562 and HL60. Cell proliferation was examined by CCK8 and Edu staining. Annexin V and TUNEL assays were… More >

QIANSHAN TAO^#, QING ZHANG^#, HUIPING WANG, HAO XIAO, MEI ZHOU, LINLIN LIU, HUI QIN, JIYU WANG, FURUN AN, ZHIMIN ZHAI^*, YI DONG^*

BIOCELL, Vol.46, No.1, pp. 159-169, 2022, DOI:10.32604/biocell.2021.014139

Abstract Acute myeloid leukemia (AML) is regarded as a stem cell disease. However, no one unique marker is expressed on leukemia stem cells (LSC) but not on leukemic blasts nor normal hematopoietic stem cells (HSC). CD34⁺ CD38- with or without CD123 or CD44 subpopulations are immunophenotypically defined as putative LSC fractions in AML. Nevertheless, markers that can be effectively and simply held responsible for the intrinsical heterogeneity of LSC is still unclear. In the present study, we examined the frequency of three different LSC subtypes (CD34⁺ CD38^-, CD34⁺ CD38^- CD123⁺ , CD34⁺ CD38^- CD44⁺ ) in AML at diagnosis. We then… More >